Page 362 - Binder2

● Therapeutic design can be iterative, not locked in
by massive infrastructure investments.

This new terrain favors agility over scale, openness over
secrecy, biology over machinery. It brings power closer to
patients, providers, and public health systems. It builds
medicine not around exclusivity—but around
reproducibility and access.

Pharma’s Worst Nightmare

And that, more than anything, is why edible biologics have
been met with indifference, skepticism, or polite dismissal
by those in power.

Because the nightmare isn’t that they won’t work.
The nightmare is that they will.

That a capsule of freeze-dried lettuce could challenge a
billion-dollar biologic.
That a greenhouse in Nairobi could make medicine as
effectively as a plant in New Jersey.
That the control mechanisms—patents, manufacturing
monopolies, delivery devices, pricing power—could be
replaced by something radically simpler.

This isn’t a threat of competition.
It’s a threat of transformation.

And when that happens—not if, but when—the industry
will face a reckoning:

● Not because it didn’t know.
● Not because it wasn’t warned.

360